文献速递前列腺增生与排尿功能障碍

非神经源性下尿路症状联合药物治疗的系统综述

Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms.
PubMed 文献 · Eur Urol · 2018-10-04

该系统综述分析了男性和女性下尿路症状(LUTS)联合治疗的疗效与不良事件,检索PubMed/Medline、Web of Science和Cochrane数据库,共纳入58篇文献。男性LUTS研究最多的联合方案是α1-肾上腺素受体拮抗剂联合5α-还原酶抑制剂,对中重度LUTS且有疾病进展风险者更有效,夜尿改善也显著优于单药。抗胆碱能药(尤其索利那新)联合米拉贝隆在男女LUTS中较单药更有效改善尿失禁和急迫性尿失禁发作,且不增加不良事件。女性激素治疗联合抗胆碱能药似乎无用。

要点

  • 男性LUTS:α1受体拮抗剂+5α还原酶抑制剂对中重度且有进展风险者更有效,夜尿改善优于单药。
  • 男女LUTS:索利那新等抗胆碱能药+米拉贝隆改善尿失禁和急迫性尿失禁,不增加不良事件。
  • 女性LUTS:激素治疗联合抗胆碱能药似乎无用。

核心结论

  • 联合治疗可优化单药疗效不足者的效果,实现更个体化的LUTS管理,兼顾疗效与耐受性。

研究设计与样本

  • 系统综述,检索PubMed/Medline、Web of Science和Cochrane数据库,男性文献检索2012年3月至2017年12月,女性1988年1月至2017年12月,共纳入58篇论文。

主要发现

  • 男性LUTS研究最多的联合方案是α1-肾上腺素受体拮抗剂/5α-还原酶抑制剂,对中重度LUTS且有疾病进展风险者多项结局更有效,夜尿改善显著优于单药。
  • 男女LUTS中抗胆碱能药(尤其索利那新)联合米拉贝隆较单药更有效改善尿失禁和急迫性尿失禁发作及其他客观和主观指标,不良事件无相关增加。
  • 女性LUTS中激素治疗联合抗胆碱能药似乎无用。

临床怎么用

  • 对单药疗效不足的男性和女性LUTS患者,可考虑联合治疗以优化疗效并个体化平衡疗效与耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Several drugs are approved and available for the treatment of lower urinary tract symptoms (LUTS) in men and women. However, the vast majority of available data, upon which the approval and recommendation in guidelines are based, considered only the role of the monotherapies and did not evaluate possible combination therapies. OBJECTIVE: This systematic review analyzes the efficacy and adverse events of combination therapies for male and female LUTS. EVIDENCE ACQUISITION: A systematic literature search in the PubMed/Medline, Web of Science, and Cochrane databases was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement to identify clinical trials, randomized controlled trials, meta-analyses, and guidelines on male and female LUTS combination therapy published from March 2012 to December 2017 for men (in order to update a previous men-focused work) and from January 1988 to December 2017 for women. A total of 58 papers were identified. EVIDENCE SYNTHESIS: The most studied combination therapy for the treatment of male LUTS is the α1-adrenoceptor antagonist/5α-reductase inhibitor combination. This combination seems to be more efficacious in terms of several outcome variables, in particular in men who have moderate-to-severe LUTS and are at risk of disease progression. Also in terms of nocturia improvements, this combination is significantly more effective than the monotherapy. The other often studied combination treatment, in both male and female patients with LUTS, was the combination of antimuscarinics (in particular solifenacin) and mirabegron. This combination seems to be more effective in comparison with the monotherapies with respect to urinary incontinence and urgency urinary incontinence episodes and several other objective and subjective parameters, without relevant increase of adverse events. The combination of hormone therapy and antimuscarinics in women with LUTS does not seem to be useful. CONCLUSIONS: For the treatment of LUTS in men and women, combination therapy appears to be a promising option to optimize the efficacy of the available drugs for those who do not experience sufficient benefit with monotherapy. This add-on scenario offers the possibility to have a more tailored approach to the management of LUTS, always seeking the optimal balance between efficacy and tolerability for a given patient. PATIENT SUMMARY: Some combination of drugs may offer advantages over monotherapies for the treatment of voiding and storage complaints in men and women.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Serati M, Andersson KE, Dmochowski R, et al. Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. Eur Urol. 2018. PMID: 30293906. doi:10.1016/j.eururo.2018.09.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。